The economics of the NHS cancer drugs fund

Applied Health Economics and Health Policy

Volumn 9, Issue 3, 2011, Pages 137-138

  Maynard, Alan ^a   Bloor, Karen ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Antineoplastics; Cancer; Health Policy; Pharmaco Economics

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER DRUG FUND; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FINANCIAL MANAGEMENT; HEALTH CARE AVAILABILITY; HEALTH CARE FINANCING; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; NEOPLASM; NOTE; OUTCOME ASSESSMENT; PATIENT CARE; REIMBURSEMENT;

ANTINEOPLASTIC AGENTS; GREAT BRITAIN; STATE MEDICINE;

EID: 79955094136     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11585750-000000000-00000     Document Type: Note

References (5)

1. Department of Health. Cancer Drugs Fund will provide £200million a year [press release; online]. Available from URL: http://www.dh.gov.uk/en/ MediaCentre/Pressreleases/DH-120941 [Accessed 2011 Mar 1]
2. Appleby J. Does poor health justify NHS reform? BMJ 2011 Jan 27; 342: d566
3. Haynes J. Expenditure on healthcare in the UK. London: Office ofNational Statistics, 2010
4. National Institute for Health and Clinical Excellence. Appraising treatments which may extend life, at the end of life. London: NICE, 2009 Aug [online]. Available from URL: http://www.nice.org.uk/aboutnice/howwework/ devnicetech/endoflifetreatments.jsp [Accessed 2011 Mar 1]
5. National Institute for Health and Clinical Excellence [online]. Available from URL: http://nice.org.uk [Accessed 2011 Mar 1]